Eisai Recognized as “2025 Kenko Investment for Health” for the First Time and Certified as “Outstanding Organization Of Kenko Investment for Health Program (White 500)” for the Sixth Time
Japan’s Telecommunications Carriers Enhance Disaster Response with On-site Training for Joint Use of Marine Vessels
Unmanned Aerial Vehicles Being Developed by MHI Used in Demonstration of Automated Transport and Unloading of Heavy Cargo in Disaster Areas
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia
Prideone Entertainment announces concept for post-war film to mark 80th anniversary of the end of World War II
NTT and DOCOMO Successfully Demonstrates On-Demand Unified Control of Computing Services Through Network and Service Integration
Space Compass and NTT DOCOMO Successfully Demonstrate Data Connectivity to 4G Devices via HAPS at 20 km Above Kenya
TOPPAN and DOCOMO Agree to Innovate Next-Generation 6G Services Using FEEL TECH Communication Technology
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer’s Disease
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone
